A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development.
The abstract entitled ‘Interim Safety and Efficacy Data from a Phase 1 Clinical Trial of Sustained-release Axitinib Hydrogel Implant (OTX-TKI) in Wet AMD Subjects’ was presented at the American Academy of Ophthalmology (AAO) meeting in Chicago, USA, 30 September – 3 October 2022.
- What are the limitations of intravitreal injections of anti-vascular endothelial growth factor agents in the treatment of wet age-related macular degeneration? (0:20)
- What is OTX-TKI and what are its potential advantages? (1:23)
- What were the aims, design and eligibility criteria of the study you presented? (2:11)
- What were the interim efficacy and safety findings? (3:21)
- What will be the next steps in the clinical development of OTX-TKI? (5:09)
Disclosures: Dilsher Dhoot is on the advisory board, a consultant for and has received honoraria from Alimera Sciences, Allergan, Apellis, Bausch and Lomb, Bayer, Coherus, Eyepoint, Genentech, Novartis, Regeneron, RegenXBio and Roche. He has received grant or research support from Allergan, Genentech and Regeneron and is on the speaker’s bureau for Alimera, Apellis, Eyepoint, Genentech and Regeneron.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of AAO 2022
Access more content on Macular Degeneration here
Share this Video
Related Videos In Macular Degeneration
Jordana Fein, ARVO 2023: Phase II CANDELA study post hoc analysis: intravitreal aflibercept injection 8 mg versus 2 mg
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]
Jordana Fein, ARVO 2023: Current therapeutic options for neovascular age-related macular degeneration
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!